The session will address:
• Why deprioritized compounds still offer the potential to help address unmet medical needs for certain patient communities and are worth advancing.
• Barriers to developing medicines for specific patient populations and how to get innovation to where it’s needed.
• Different mechanisms for bringing products to market by affiliating with organizations that can improve access.
• What’s changing with the traditional model and why now is the right time for change.
Session ID: 560554